12.31
0.31 (2.58%)
| Previous Close | 12.00 |
| Open | 12.00 |
| Volume | 582,738 |
| Avg. Volume (3M) | 1,342,231 |
| Market Cap | 760,257,664 |
| Price / Earnings (TTM) | 31.56 |
| Price / Sales | 5.70 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 3.86% |
| Operating Margin (TTM) | 51.85% |
| Diluted EPS (TTM) | 0.120 |
| Quarterly Revenue Growth (YOY) | 7,882.00% |
| Total Debt/Equity (MRQ) | 15.21% |
| Current Ratio (MRQ) | 5.61 |
| Operating Cash Flow (TTM) | 34.67 M |
| Levered Free Cash Flow (TTM) | 40.54 M |
| Return on Assets (TTM) | -0.40% |
| Return on Equity (TTM) | 2.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Monte Rosa Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.67 |
|
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.73% |
| % Held by Institutions | 101.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nea Management Company, Llc | 30 Jun 2025 | 7,692,298 |
| Bvf Inc/Il | 30 Jun 2025 | 5,660,132 |
| Versant Venture Management, Llc | 30 Jun 2025 | 5,652,922 |
| Baker Bros. Advisors Lp | 30 Jun 2025 | 4,916,095 |
| Avoro Capital Advisors Llc | 30 Jun 2025 | 3,725,000 |
| Suvretta Capital Management, Llc | 30 Jun 2025 | 3,360,000 |
| Aisling Capital Management Lp | 30 Jun 2025 | 1,472,331 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2025 | Announcement | Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates |
| 03 Nov 2025 | Announcement | Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences |
| 24 Oct 2025 | Announcement | Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases |
| 15 Sep 2025 | Announcement | Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases |
| 02 Sep 2025 | Announcement | Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences |
| 07 Aug 2025 | Announcement | Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |